Gasporox (GPX) Q3 2024 earnings summary

Executive summary

• Revenue for Q3 2024 increased 14% year-over-year to 7,767 KSEK, driven by higher demand and portfolio expansion.

• EBITDA was positive at 87 KSEK, though operating income remained negative at -1,334 KSEK.

• For the first nine months, revenue grew 9% to 26,097 KSEK, with a negative operating result of -1,098 KSEK.

• Liquidity remains strong with 8,424 KSEK in cash, supporting ongoing investments and market expansion.

• Product launches and international event participation strengthened market presence, with new solutions targeting the pharmaceutical sector.

Financial highlights

• Q3 2024 revenue: 7,767 KSEK (up from 6,787 KSEK in Q3 2023); nine-month revenue: 26,097 KSEK (up from 24,025 KSEK year-over-year).

• Q3 EBITDA: 87 KSEK (290 KSEK in Q3 2023); Q3 operating income: -1,334 KSEK (-768 KSEK in Q3 2023).

• Cash flow for Q3: -2,225 KSEK; cash at period end: 8,424 KSEK.

• Equity at period end: 21,532 KSEK; equity ratio: 52%.

• EPS for Q3: -0.17 SEK (-0.11 SEK in Q3 2023); nine-month EPS: -0.18 SEK (-0.04 SEK year-over-year).

Outlook and guidance

• Management expects continued strong revenue growth and broader market establishment in coming years.

• No additional capital needs anticipated to reach positive cash flow, barring major strategic changes or market shifts.

• Focus remains on expanding product portfolio and entering new market segments, especially pharmaceuticals.